Latest Pirfenidone Stories
EasyOne Pro Used at San Antonio Free Clinic to Help Diagnose and Manage PF ANDOVER, Mass., March 5, 2015 /PRNewswire/ -- ndd
First FDA Approved Treatments in United States for Devastating Lung Disease Affecting More than 200,000 Americans, with Survival Rate of Just Three to Five Years CHICAGO, Oct.
FLINT, Mich., Oct.
-- Roche to acquire InterMune for $74.00 per share -- BASEL, Switzerland, Aug. 24, 2014 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) and InterMune, Inc.
-- Transformational H1 2014 includes presentation of Phase 3 ASCEND data, NDA resubmission and target PDUFA date of Nov. 23 for pirfenidone in U.S. - BRISBANE, Calif., Aug.
SAN DIEGO, Aug. 5, 2014 /PRNewswire/ -- Genoa Pharmaceuticals, the leader in inhaled medicines for pulmonary fibrosis, today announced the U.S.
BRISBANE, Calif., July 28, 2014 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that it will release its second quarter 2014 financial results at the close of the U.S.
Nintedanib and Pirfenidone Received Breakthrough Therapy Designation by the U.S.
BRISBANE, Calif., July 17, 2014 /PRNewswire/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that pirfenidone has been granted Breakthrough Therapy Designation from the U.S.
BRISBANE, Calif., May 27, 2014 /PRNewswire/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that it has resubmitted its pirfenidone New Drug Application (NDA) to the U.S.
- A young chicken: also used as a pet name for children.